Carbidopa
Term · Oncology and biomedicine · MLC-T-ONC-012242
A hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors.
| Identifier | MLC-T-ONC-012242 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | alpha-methyldopahydrazine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012242",
"term": "Carbidopa",
"field": "Oncology and biomedicine",
"definition": "A hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors.",
"synonyms": [
"alpha-methyldopahydrazine"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/carbidopa/"
}
Record 4,139 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.